Accéder au contenu
MilliporeSigma

Photon activation therapy of RG2 glioma carrying Fischer rats using stable thallium and monochromatic synchrotron radiation.

Physics in medicine and biology (2012-12-04)
Crister Ceberg, Bo-Anders Jönsson, Yolanda Prezado, Tobias Pommer, Henrietta Nittby, Elisabet Englund, Gustav Grafström, Anneli Edvardsson, Anna Stenvall, Susanne Strömblad, Karin Wingårdh, Bertil Persson, Hélène Elleaume, Bo Baldetorp, Leif G Salford, Sven-Erik Strand
RÉSUMÉ

75 RG2 glioma-carrying Fischer rats were treated by photon activation therapy (PAT) with monochromatic synchrotron radiation and stable thallium. Three groups were treated with thallium in combination with radiation at different energy; immediately below and above the thallium K-edge, and at 50 keV. Three control groups were given irradiation only, thallium only, or no treatment at all. For animals receiving thallium in combination with radiation to 15 Gy at 50 keV, the median survival time was 30 days, which was 67% longer than for the untreated controls (p = 0.0020) and 36% longer than for the group treated with radiation alone (not significant). Treatment with thallium and radiation at the higher energy levels were not effective at the given absorbed dose and thallium concentration. In the groups treated at 50 keV and above the K-edge, several animals exhibited extensive and sometimes contra-lateral edema, neuronal death and frank tissue necrosis. No such marked changes were seen in the other groups. The results were discussed with reference to Monte Carlo calculated electron energy spectra and dose enhancement factors.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Thallium, granular, ≤6 mm diameter, 99.9% trace metals basis